Lineage Cell Therapeutics Inc (LCTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lineage Cell Therapeutics Inc (LCTX) has a cash flow conversion efficiency ratio of -0.174x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.62 Million) by net assets ($20.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lineage Cell Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how Lineage Cell Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Lineage Cell Therapeutics Inc (LCTX) total liabilities for a breakdown of total debt and financial obligations.
Lineage Cell Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lineage Cell Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Weifu High Tech Group
SHE:200581
|
0.049x |
|
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
|
-0.103x |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
0.051x |
|
Shandong Kehui Power Automation Co Ltd
SHG:688681
|
0.036x |
|
NOCIL Limited
NSE:NOCIL
|
0.076x |
|
Ihlas Haber Ajansi AS
IS:IHAAS
|
-0.228x |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
0.121x |
|
Henan BCCY Environmental Energy Co. Ltd
SHE:300614
|
N/A |
Annual Cash Flow Conversion Efficiency for Lineage Cell Therapeutics Inc (1991–2024)
The table below shows the annual cash flow conversion efficiency of Lineage Cell Therapeutics Inc from 1991 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Lineage Cell Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $77.01 Million | $-23.09 Million | -0.300x | +34.90% |
| 2023-12-31 | $62.02 Million | $-28.57 Million | -0.461x | -3228.58% |
| 2022-12-31 | $71.94 Million | $1.06 Million | 0.015x | +105.68% |
| 2021-12-31 | $90.90 Million | $-23.56 Million | -0.259x | -24.83% |
| 2020-12-31 | $95.13 Million | $-19.75 Million | -0.208x | +27.69% |
| 2019-12-31 | $111.25 Million | $-31.95 Million | -0.287x | +14.22% |
| 2018-12-31 | $92.25 Million | $-30.88 Million | -0.335x | -80.20% |
| 2017-12-31 | $164.26 Million | $-30.52 Million | -0.186x | +42.72% |
| 2016-12-31 | $130.51 Million | $-42.33 Million | -0.324x | +44.34% |
| 2015-12-31 | $76.45 Million | $-44.54 Million | -0.583x | +5.94% |
| 2014-12-31 | $62.72 Million | $-38.85 Million | -0.619x | +11.28% |
| 2013-12-31 | $42.26 Million | $-29.51 Million | -0.698x | +13.80% |
| 2012-12-31 | $24.29 Million | $-19.68 Million | -0.810x | -147.04% |
| 2011-12-31 | $41.46 Million | $-13.59 Million | -0.328x | -109.58% |
| 2010-12-31 | $49.43 Million | $-7.73 Million | -0.156x | +59.43% |
| 2009-12-31 | $11.05 Million | $-4.26 Million | -0.386x | -204.49% |
| 2008-12-31 | $-4.35 Million | $-1.60 Million | 0.369x | -9.33% |
| 2007-12-31 | $-3.05 Million | $-1.24 Million | 0.407x | -39.85% |
| 2006-12-31 | $-1.87 Million | $-1.26 Million | 0.677x | -90.59% |
| 2005-12-31 | $-196.58K | $-1.41 Million | 7.194x | +261.40% |
| 2004-12-31 | $344.77K | $-1.54 Million | -4.457x | -1756.11% |
| 2003-12-31 | $-2.43 Million | $-654.14K | 0.269x | -85.20% |
| 2002-12-31 | $-1.17 Million | $-2.13 Million | 1.818x | -94.39% |
| 2001-12-31 | $-99.09K | $-3.21 Million | 32.392x | +978.80% |
| 2000-12-31 | $1.32 Million | $-4.86 Million | -3.686x | -326.31% |
| 1999-12-31 | $5.08 Million | $-4.39 Million | -0.865x | +1.19% |
| 1998-12-31 | $2.40 Million | $-2.10 Million | -0.875x | -337.50% |
| 1997-12-31 | $6.50 Million | $-1.30 Million | -0.200x | +73.33% |
| 1996-12-31 | $2.80 Million | $-2.10 Million | -0.750x | 0.00% |
| 1995-12-31 | $2.80 Million | $-2.10 Million | -0.750x | -20.00% |
| 1994-12-31 | $3.20 Million | $-2.00 Million | -0.625x | -126.56% |
| 1993-12-31 | $5.80 Million | $-1.60 Million | -0.276x | +27.85% |
| 1992-12-31 | $3.40 Million | $-1.30 Million | -0.382x | -193.14% |
| 1991-12-31 | $4.60 Million | $-600.00K | -0.130x | -- |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more